PT Kalbe Farma Tbk (PTKFY)
OTHER OTC:PTKFY
PTKFY Stock Chart & Stats
$14.66
$0.00(0.00%)
At close: 4:00 PM EST
$14.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.07 - $19.68
Previous CloseN/A
Volume58.00
Average Volume (3M)154.00
Market Cap
$2.67B
Enterprise Value$39.92T
Total Cash (Recent Filing)$4.49T
Total Debt (Recent Filing)$297.28B
Price to Earnings (P/E)20.5
Beta0.54
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)0.27
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio2.39
Price to Book (P/B)1.89
Price to Sales (P/S)1.24
P/FCF Ratio17.42
Enterprise Value/Market Cap14.94K
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda7.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a growing equity base give Kalbe durable financial flexibility. This reduces solvency risk, supports continued R&D, capex, and dividend capacity, and allows the company to absorb shocks or pursue selective M&A without stressing cash flows over the next several quarters.
Diversified Healthcare FranchiseA multi-segment business (prescription drugs, OTC, nutritionals, distribution) creates structural revenue diversification and cross-channel scale. Broad domestic distribution and export channels reduce single-market risk and support steady demand and margin stability versus single-product peers.
Consistent Positive Cash GenerationPersistent positive operating and free cash flow provides a durable source to fund dividends, working capital, and reinvestment. Even with some variability, multi-year free cash generation underpins capital allocation flexibility and supports shareholder returns over the medium term.
Bears Say
Slowing Revenue GrowthDecelerating top-line expansion signals maturation or increasing competitive pressure in key segments. Slower revenue growth reduces operating leverage and limits scope to expand margins or reinvest at prior rates, constraining EPS and return improvement over the coming quarters.
Margin CompressionSustained margin erosion undermines return on capital and free cash flow per unit of sales. If cost or pricing pressures persist, compressed margins will limit internal funding for growth, dividends, or margin-recovery investments, reducing long-term profitability resilience.
Uneven Cash ConversionVariable cash conversion and episodic FCF declines weaken earnings quality and make future cash available for dividends or investments less predictable. This increases execution risk for long-term plans and may force more conservative capital allocation during weaker conversion periods.
PT Kalbe Farma Tbk News
PTKFY FAQ
What was PT Kalbe Farma Tbk’s price range in the past 12 months?
PT Kalbe Farma Tbk lowest stock price was $11.06 and its highest was $19.68 in the past 12 months.
What is PT Kalbe Farma Tbk’s market cap?
PT Kalbe Farma Tbk’s market cap is $2.67B.
When is PT Kalbe Farma Tbk’s upcoming earnings report date?
PT Kalbe Farma Tbk’s upcoming earnings report date is Apr 23, 2026 which is in 18 days.
How were PT Kalbe Farma Tbk’s earnings last quarter?
PT Kalbe Farma Tbk released its earnings results on Mar 30, 2026. The company reported $0.274 earnings per share for the quarter, beating the consensus estimate of N/A by $0.274.
Is PT Kalbe Farma Tbk overvalued?
According to Wall Street analysts PT Kalbe Farma Tbk’s price is currently Overvalued.
Does PT Kalbe Farma Tbk pay dividends?
PT Kalbe Farma Tbk pays a Annually dividend of $0.442 which represents an annual dividend yield of 3.33%. See more information on PT Kalbe Farma Tbk dividends here
What is PT Kalbe Farma Tbk’s EPS estimate?
PT Kalbe Farma Tbk’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PT Kalbe Farma Tbk have?
PT Kalbe Farma Tbk has 234,066,960 shares outstanding.
What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
PT Kalbe Farma Tbk reported an EPS of $0.274 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.227%.
Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
Currently, no hedge funds are holding shares in PTKFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PT Kalbe Farma Tbk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.75%
12-Months-Change
Fundamentals
Return on Equity
15.61%
Trailing 12-Months
Asset Growth
3.35%
Trailing 12-Months
Company Description
PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Technical Analysis
Grifols SA
―
SRx Health Solutions
―
Scilex Holding Company
―
Organon
―
Citius Oncology
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---